Pharmacokinetic characterization of favipiravir in patients with COVID‐19-Reference-Cited by-同舟云学术

Pharmacokinetic characterization of favipiravir in patients with COVID‐19

Published:2022-02-08 Issue:7 Volume:88 Page:3516-3522
ISSN:0306-5251
Container-title:British Journal of Clinical Pharmacology
language:en
Short-container-title:Brit J Clinical Pharma

Author:

Gülhan Rezzan¹^ORCID,Eryüksel Emel²^ORCID,Gülçebi İdriz Oğlu Medine¹^ORCID,Çulpan Yekta¹^ORCID,Toplu Aylin¹^ORCID,Kocakaya Derya²^ORCID,Tigen Elif³^ORCID,Ertürk Şengel Buket³^ORCID,Sili Uluhan³^ORCID,Olgun Yıldızeli Şehnaz²^ORCID,Balcan Mehmet Baran²^ORCID,Elçi Abdullah⁴,Bulut Cenk⁴,Karaalp Atila¹^ORCID,Yananlı Hasan Raci¹^ORCID,Güner Abdullah Emre⁵^ORCID,Hatipoğlu Mustafa⁵,Karakurt Sait²^ORCID,Korten Volkan³^ORCID,Ratnaraj Neville⁶,Patsalos Philip⁶^ORCID,Ay Pınar⁷^ORCID,Onat Filiz¹⁸^ORCID

Affiliation:

1. Department of Medical Pharmacology Marmara University School of Medicine Istanbul Turkey

2. Department of Pulmonary Medicine and Critical Care Marmara University School of Medicine Istanbul Turkey

3. Department of Infectious Disease and Clinical Microbiology Marmara University School of Medicine Istanbul Turkey

4. Istanbul Health Directorate Public Health Laboratory‐3 Istanbul Turkey

5. Istanbul Health Directorate Istanbul Turkey

6. Department of Clinical and Experimental Epilepsy University College London, Queen Square Institute of Neurology London UK

7. Department of Public Health Marmara University School of Medicine Istanbul Turkey

8. Department of Medical Pharmacology Acibadem Mehmet Ali Aydinlar University School of Medicine Istanbul Turkey

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15227

Reference27 articles.

1. WHOWHO Director‐General's remarks at the media briefing on 2019‐nCoV on 11 February 2020.http://www.who.int/dg/speeches/detail/who-director-general-s-remarks-at-the-media-briefing-on-2019-ncov-on-11-february-2020. Accessed May 22 2021.

2. WHO.WHO Coronavirus (COVID‐19) Dashboard;2021.https://covid19.who.int. Accessed May 23 2021.

3. Report on the Deliberation Results Avigan Tablet 200 mg by Pharmaceuticals and Medical Devices Agency (PMDA).Japan:Evaluation and Licensing Division Pharmaceutical and Food Safety Bureau Ministry of Health Labour and Welfare;2014.https://www.pmda.go.jp/files/000210319.pdf

4. Avigan tablet 200 mg [package insert]. English translation by Toyama Chemical Co. Ltd;2017.

5. The efficacy and safety of Favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An ultrasensitive green synchronous factorized spectrofluorimetric approach for the simultaneous determination of Favipiravir and Molnupiravir: Application to pharmaceutical, environmental, and biological matrices;Luminescence;2024-08

2. Favipiravir pharmacokinetics in COVID-19 patients with moderate to severe kidney dysfunction: Lessons learned;Int. Journal of Clinical Pharmacology and Therapeutics;2024-08-01

3. Unveiling therapeutic dynamics: An in-depth comparative analysis of neutralizing monoclonal antibodies and favipiravir in alleviating COVID-19 outpatients impacts among middle-aged and special populations (MA-FAST);Journal of Infection and Public Health;2024-07

4. Human bronchopulmonary disposition and plasma pharmacokinetics of oral bemnifosbuvir (AT-527), an experimental guanosine nucleotide prodrug for COVID-19;Journal of Antimicrobial Chemotherapy;2024-05-06

5. Green chemometric-assisted UV-spectrophotometric methods for the determination of favipiravir, cefixime and moxifloxacin hydrochloride as an effective therapeutic combination for COVID-19; application in pharmaceutical form and spiked human plasma;BMC Chemistry;2024-04-05